ImmunityBio Inc. (NASDAQ:IBRX) saw an upside of 3.34% to close Tuesday at $1.70 after adding $0.06 on the day. The 5-day average trading volume is 2,241,640 shares of the company’s common stock. It has gained $2.0400 in the past week and touched a new high 1 time within the past 5 days. An average of 2,591,735 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,424,758.
IBRX’s 1-month performance is -35.85% or -$1.1100 on its low of $1.6201 reached on 08/21/23. The company’s shares have touched a 52-week low of $1.21 and high of $7.80, with the stock’s rally to the 52-week high happening on 05/09/23. YTD, IBRX has lost -66.47% or -$3.3700 and has reached a new high 4 times. However, the current price is down -78.21% from the 52-week high price.
Valuation Metrics
IBRX stock has a beta of 1.40. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1297.55.
ImmunityBio Inc.’s quick ratio for the period ended June 29 was 0.10, with the current ratio over the same period at 0.10. The trailing 12-month EBITDA margin is -136010.42%. The firm’s gross profit as reported stood at $351.54 million against revenue of $0.24 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 31.4% to -$137.88 million, while revenue of -$116.34 million was 15.62% off the previous quarter. Analysts expected IBRX to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.32, representing a -39.10% surprise. EBITDA for the quarter stood at more than -$68.17 million. IBRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 936.41 million, with total debt at $819.26 million. Shareholders hold equity totaling $456.25 million.
Let’s look briefly at ImmunityBio Inc. (IBRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 33.32% to suggest the stock is trending Neutral, with historical volatility in this time period at 95.93%.
The stock’s 5-day moving average is $1.7910, reflecting a -13.27% or -$0.2600 change from its current price. IBRX is currently trading -33.98% above its 20-day SMA, -5.56% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -40.14% and SMA200 by-68.34%.
Stochastic %K and %D was 16.01% and 23.39% and the average true range (ATR) pointed at 0.1853. The RSI (14) points at 34.59%, while the 14-day stochastic is at 14.02% with the period’s ATR at 0.1968. The stock’s 9-day MACD Oscillator is pointing at -0.0961 and -0.1270 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for ImmunityBio Inc. (NASDAQ: IBRX), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock. Analysts offering their rating for IBRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate IBRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is IBRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $5.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for ImmunityBio Inc. (IBRX) stock is $5.00.
